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Abstract.  Two skeletal muscle-specific regulatory fac- 
tors,  myogenin and MyoD1, share extensive homology 
within a myc similarity region and have each been 
shown to activate the morphologic and molecular 
events associated with myogenesis after transfection 
into nonmyogenic cells. The BC3H1 muscle cell line 
expresses myogenin and other muscle-specific genes, 
but does not express MyoDl during differentiation. 
BC3H1 cells also do not upregulate or-cardiac actin or 
fast myosin light chain, nor do they form multinucle- 
ate myotubes during differentiation. In this study, we 
examined the basis for the lack of MyoDl expression 
in BC3H1 cells and investigated whether their failure 
to express MyoD1  is responsible for their defects in 
differentiation. We report that expression of an exoge- 
nous MyoD1 cDNA in BC3H1 cells was sufficient to 
elevate the expression of o~-cardiac actin and fast myo- 
sin light chain, and to convert these cells to a  pheno- 
type that forms multinucleate myotubes during 
differentiation. Whereas myogenin and MyoD1 posi- 
tively regulated their own expression in transfected 
1011/2  cells, they could not, either alone or in combi- 
nation, activate MyoD1 expression in BC3H1 cells. Ex- 
posure of BC3HI  cells to 5-azacytidine also failed to 
activate MyoD1 expression or to rescue the cell's abil- 
ity to fuse. These results suggest that BC3H1 cells may 
possess a defect that prevents activation of the MyoDl 
gene by MyoD1 or myogenin. That an exogenous 
MyoD1 gene could rescue those aspects of the 
differentiation program that are defective in BC3H1 
cells also suggests that the actions of MyoDl and myo- 
genin are not entirely redundant and that MyoDl may 
be required for activation of the complete repertoire of 
events associated with myogenesis. 
D 
FFERENTIATION of skeletal myoblasts involves irre- 
versible conversion to a postmitotic state, fusion to 
form  multinucleate myotubes,  and  transcriptional 
activation of muscle-specific genes. Three muscle-specific 
regulatory factors, MyoDl (3), myogenin (5, 40, and myf-5 
(2), have recently been identified and shown to share a high 
degree of homology within a domain related to the myc pro- 
tein family. When transfected into fibroblasts under the tran- 
scriptional control of a constitutive promoter, each of these 
genes can activate the morphologic and molecular events of 
myogenesis. 
Initial evidence for a  hierarchy of myogenic regulatory 
genes was obtained from studies that showed that exposure 
of the multipotential mesodermal stem cell line C3H10T1/2 
to the demethylating  agent 5-azacytidine resulted in the cells' 
conversion to myoblasts at high frequency (25-50%)  (37). 
These observations led to the proposal that hypomethylation 
of a single gene or a few closely linked loci was responsible 
for conversion to the myogenic lineage (13). MyoD1 expres- 
sion  is  activated  in  5-azacytidine-derived myoblasts  (3); 
however, it is not known whether the MyoD1 gene is the ac- 
tual target for demethylation by 5-azacytidine. Nonetheless, 
the expression of MyoD1 as a result of 5-azacytidine treat- 
ment indicates that the MyoD1 gene itself  or a gene that regu- 
lates MyoD1 is activated in 10TI/2 cells as a consequence of 
demethylation. In this regard, Emerson and co-workers have 
identified a gene referred to as myd, that efficiently converts 
10"I"1/2 cells  to  myoblasts  when  it  is  transfected  as  de- 
methylated cosmid DNA (27). MyoDl and myogenin are ex- 
pressed by myd-transfected 10"I'1/2 cells, which led to the 
proposal that these genes might be regulated by myd in a de- 
pendent myogenic regulatory cascade (27).  Recent studies 
by Thayer et al. (38) also showed that MyoD1 positively au- 
toregulates its own expression and that myogenin and MyoD1 
regulate each others' expression.  Similarly, MyoD1  is ex- 
pressed by myf-5-transfected 10T1/2 cells (2). 
The mouse muscle cell line BC3H1 has been used exten- 
sively as  a  model  for  studying the  mechanisms  through 
which growth factors and oncogenes regulate myogenesis 
(10, 12, 17, 21, 22, 25, 30, 31, 32, 39). When maintained in 
the  presence  of high  concentrations of serum,  fibroblast 
growth factor, or type-/~ transforming growth factor, BC3H1 
cells exhibit a fibroblast-like morphology and do not express 
muscle-specific genes.  Upon  exposure  to  growth  factor- 
deficient medium, these cells exit the cell cycle, and an array 
of skeletal muscle gene products is induced. However, unlike 
normal skeletal muscle cells, BC3H1 cells do not fuse or 
commit to terminal differentiation, nor do these cells express 
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myosin light chain (MLC-lf) ~  (36) also do not appear to be 
upregulated to normal levels in these cells. The lack of Myo- 
D1  expression in  BC3H1 cells suggests  that the myogenic 
program can be activated, at least in part, through a MyoD1- 
independent  mechanism.  That  finding  initially  led  us  to 
search for regulatory genes related structurally or function- 
ally to MyoD1. Using the myc similarity region of a MyoD1 
cDNA as a probe to screen a BC3H1 cDNA library under 
conditions  of reduced  stringency, a  MyoD-related cDNA 
was identified (5). This cDNA was found to be homologous 
to a rat cDNA referred to as myogenin, which was isolated 
by subtraction-hybridization (41). Subsequent studies showed 
that  myogenin possessed  the  potential  to  induce  muscle- 
specific genes and fusion in transfected 10T1/2 cells (5). 
That BC3H1 cells express myogenin at high levels but do 
not form myotubes suggests that the actions of myogenin are 
more restricted in these cells than in 10T1/2 cells. To explore 
the mechanism that prevents myogenin from activating the 
complete myogenic program in BC3H1 cells, we examined 
whether the MyoD1 gene can be expressed in BC3H1 cells, 
and whether these cells possess the genetic potential to fully 
differentiate. We report here that expression of an exogenous 
MyoD1 cDNA in BC3H1 cells is sufficient to restore their 
ability to form multinucleate myotubes and to elevate the ex- 
pression of a-cardiac actin and MLC-If during differentia- 
tion. Whereas myogenin and MyoDl positively regulate each 
others' expression in transfected 10"I"1/2  cells, this regulatory 
interaction  is  inactive  in  BC~H1 cells,  such  that  neither 
myogenin nor MyoD1, alone or in combination, can activate 
the endogenous MyoD1 gene. These results demonstrate that 
the failure Of BC3HI  cells to activate the complete reper- 
toire of events associated with myogenesis is due to their in- 
ability to express MyoDl. The fact that neither myogenin nor 
MyoD1  are able to activate MyoD1  expression in  BC3HI 
cells also suggests that the MyoD1 gene itself has undergone 
a  stable alteration that prevents  its activation,  or that the 
regulatory pathway that activates the MyoD1 gene in 10TI/2 
fibroblasts is nonfunctional in these cells. 
Materials and Methods 
Cell Culture 
The BC3H1 (31),  C2 (42), and 101"1/2 cell lines were maintained in DME 
containing 20% FBS as described previously (21). Differentiation was initi- 
ated by replacing growth medium with differentiation medium containing 
0.5% FBS or 2% horse serum, as indicated. BC3HI  cells differentiate bet- 
ter in 0.5%  FBS,  whereas MyoDl-transfected BC3H1 cells show higher 
levels of differentiation in 2 % horse serum. For examination of the effects 
of 5-azacytidine, the cultures were treated with  10 #M 5-azacytidine for 
24 h, after which they were plated at clonal density and allowed to form 
colonies for  14 d.  The cultures  were then transferred to differentiation 
medium and analyzed for myotube formation. 
Transfections 
BC3HI  and 101"1/2 cells were transfected by calcium phosphate precipita- 
tion (8) as described previously (23) with 200 ng of pSV2neo and 4/zg of 
MyoDl or myogenin expression vectors. The expression vector pEM275 
(generously provided by C. P. Emerson, Jr. and S. Pearson-White, Univer- 
sity of Virginia), which contains a mouse MyoDl cDNA under transcrip- 
tional control of the ~-actin promoter, was used to transfect BC3H1 cells. 
1. Abbreviations used in this paper:  MLC-If, fast myosin light chain; MSV- 
LTR, Maloney sarcoma virus long terminal repeat. 
The MyoDl insert in that vector contains the complete ceding region and 
lacks ,'~500  nucleotides from the 3' untranslated region.  101"1/2 cells were 
transfected using a MyoDl expression vector designated pEMCI ls (gener- 
ously provided by A. Lassar, Fred Hutchinson Cancer Research Center), 
which contains mouse MyoDl under control of the Malone)' sarcoma virus 
long terminal repeat (3).  A mouse myogenin cDNA was also cloned into 
this vector and has been described previously (5).  48 h after transfection, 
plates were transferred to growth medium containing 20%  FBS and 400 
p.g/ml G--418. After 14 d, individual clones were isolated and passaged into 
stable cell lines. 
RNA Isolation and Northern Analysis 
Total cellular RNA was isolated using the guanidinium isothiocyanate pro- 
cedure (5). 10 #g of RNA was electrophoresed on each lane of a denaturing 
formaldehyde agarose gel. After electrophoresis, RNA was transferred to 
nitrocellulose as described previously (32), and the blots were hybridized 
to 32p-labeled probes for MyoD1  (3), troponin-T (Tn-T) (7), myogenin (5), 
muscle creatine kinase (28), and MLC-1 f, as indicated. The M LC-I r probe 
(generously provided by Nadia Rosenthal, Boston University) was derived 
from the plasmid c91-JC and contains only light chain-l-specific sequences 
from the 5' portion of the transcript. ~Cardiac actin was measured using 
a  synthetic oligomer (generously provided by Michael Schneider, Baylor 
College of Medicine) corresponding to a unique sequence within the 3' un- 
translated region (19).  DNA probes were labeled by random priming (6), 
except that the c~-cardiac actin oligomer was end labeled with T4 kinase. 
DNA Isolation and Southern Analysis 
Genomic DNA was extracted from BC3HI and C2 cells (18), digested with 
the indicated restriction enzymes, and electrophoresed on 0.8%  agarose 
gels. After its transfer to nitrocellulose, the DNA was hybridized to labeled 
probes as described above. 
Results 
BC~I1 Cells Possess a MyoD1 Gene 
A straightforward explanation for the lack of expression of 
MyoD1 by BC3H1 cells would be that the MyoD1 gene is 
deleted or rearranged such that it cannot be expressed. To 
examine  these  possibilities,  we  analyzed  genomic  DNA 
from BC3H1 cells and C2 cells, which express MyoDl, for 
the MyoD1 gene by Southern analysis. As shown in Fig.  1, 
the DNA from both muscle cell lines showed an identical 
pattern of MyoD1 hybridization. The MyoD1 gene is, there- 
fore, not deleted from the BC3H1 genome and appears not 
to be grossly rearranged, at least within the limits of resolu- 
tion of this analysis. 
Figure 1. Southern analysis of 
the  MyoDl  gene  in C2  and 
BC3H1 cells. Genomic DNA 
was isolated from BC3HI and 
C2 cells, digested with Eco RI 
(E) or Hind Ill (H) as indi- 
cated, and electrophoresed on 
a0.8% agarose  gel. After trans- 
fer to nitrocellulose,  blots were 
hybridized  to  a  full-length 
mouse MyoD1 eDNA labeled 
with 32p. Relative migrations 
of DNA  standards are  indi- 
cated. 
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Phenotype by Transfection with MyoD1 
If the  inability  of BC3H1 cells  to  form  myotubes  is  due 
solely to the lack of MyoD1 expression, BC3H1 cells should 
form myotubes after transfection with an exogenous MyoD1 
gene. If BC3H1 cells instead possess multiple genetic alter- 
ations that prevent terminal differentiation and fusion,  it is 
unlikely that these events could be rescued by transfection of 
a  single gene.  To determine whether the failure of BC3H1 
cells  to  fuse  was  due  to  the  lack  of MyoD1  expression, 
BC3H1 cells were transfected with a  mouse MyoD1 cDNA 
that  was  under  transcriptional  control  of the  /3-actin  pro- 
moter and with the neomycin resistance gene as a selectable 
marker. 
We  examined  the  morphology  of  MyoDl-transfected 
clones and found that '~25% of the colonies that had been 
transfected  with  MyoD1  formed  extensive  multinucleate 
myotubes after 4-5 d of exposure to mitogen-deficient me- 
dium. The morphologies of three representative clones that 
had acquired the ability to fuse as a result of transfection with 
the MyoDl expression vector are shown in Fig. 2. No myo- 
tubes were observed in any of the MyoDl-transfected clones 
in growth medium. Examination of several hundred colonies 
transfected with the neomycin resistance gene alone also did 
not reveal any multinucleate myotubes. 
To eliminate the possibility that the failure of the parental 
BC3H1 cells to fuse was simply due to an insufficient level 
of myogenin expression, cells were also transfected with an 
Figure  2.  Morphology  of 
BC3HI clones transfected with 
a  MyoDl  expression  vector. 
BC3H1 cells were transfected 
with pSV2neo and the MyoD1 
expression  vector  pEM275 
which contains a mouse Myo- 
D1  cDNA  under  transcrip- 
tional  control  of the  /$-actin 
promoter. 48 h after transfec- 
tion,  the  plates  were  trans- 
ferred to growth medium con- 
taining 20% FBS and 400 #g/ 
ml  G-418. After  14 d,  indi- 
vidual  clones  were  isolated 
and passaged  into stable cell 
lines. Photographs  are shown 
of  three  independent  clones 
after 5 d in differentiation me- 
dium  containing  2%  horse 
serum. 
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control of the Maloney sarcoma virus long terminal repeat 
(MSV-LTR) (5). None of the resulting clones formed myo- 
tubes after exposure to differentiation medium. We have not 
analyzed these clones in detail to confirm that they express 
myogenin at elevated levels. However, since myogenin-trans- 
fected 10"1"1/2  cells can form myotubes with levels of myoge- 
nin expression similar to those in differentiated BC3H1 cells 
(5), it is unlikely that fusion can be restored in BC3H1 cells 
simply by elevating the level of myogenin expression. These 
results support the conclusion that myogenin alone cannot in- 
duce  fusion  in  BC3H1 cells,  and  show  that  the  lack  of 
MyoD1 expression is responsible for the failure of BC3H1 
cells to form myotubes during differentiation. 
The MyoD1 Gene Cannot Be Activated by MyoD1 or 
Myogenin in BCjH1 Cells 
To confirm that the exogenous MyoD1 gene was expressed 
in the stable transfectants that had acquired the ability to 
fuse, 14 independent clones were isolated before exposure to 
differentiation medium and passaged into stable cell lines. 
RNA was then isolated from cultures in growth and differen- 
tiation media and analyzed for MyoD1 expression. 7 of the 
14 clones showed the ability to form myotubes to varying 
degrees after being expanded into cell lines. Results obtained 
with a representative fusing clone, designated BMD-1, are 
shown in Fig. 3. The transcript originating from the trans- 
fected MyoD1  gene is  '~500 nucleotides shorter than the 
complete mouse MyoD1 mRNA due to the absence of se- 
quences from the 3' untranslated region. The transfected gene 
product is  therefore distinguishable by Northern analysis. 
Although the exogenous MyoD1  gene was  expressed at a 
high level in the BMD-I cell line, there was no detectable ex- 
pression of the endogenous transcript in either growth or 
differentiating conditions.  Prolonged exposure of blots  to 
film also failed to show endogenous MyoD1 expression. We 
also examined MyoD1 expression in two independent sets of 
pooled clones containing between 25  and 50 clones each. 
Only the exogenous MyoD transcript was detectable in these 
pools (data not shown). We also used a probe from the por- 
tion of the 3' flanking region of MyoD1 that is absent from 
the transfected cDNA to confirm that the smaller transcript 
indeed arises from the endogenous gene. 
It should be pointed out that all of  the MyoD1 transfectants 
that we analyzed expressed the transfected gene at lower lev- 
els  than  the  endogenous gene  in  differentiated C2  cells. 
Nonetheless,  even when the exogenous MyoD1  transcript 
was present at levels 10-fold lower than the level of MyoD1 
in C2 cells, extensive fusion was observed upon transfer to 
Figure 3. Expression of MyoDl in Myo- 
Dl-transfected BC3H1 cells. Total cellu- 
lar  RNA  was  isolated  from  BC3H1, 
BMD-1, and C2 cells. Growth medium 
(G) contained 20% FBS; differentiation 
medium (D) contained  0.5% FBS for 
BC3HI cells, and 2% horse serum for 
BMD-I and C2 cells. RNA blots were 
hybridized  to  32p-labeled probes  for 
MyoD1. Ethidium bromide staining of 
the gel is shown to confirm that equiva- 
lent quantities of RNA were electropho- 
resed on each lane. 
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sion is not dependent simply on the level of expression of 
myogenin, but also requires additional factors. 
Whereas MyoD1 was expressed in every clone that had the 
potential  to  form myotubes,  analysis  of seven clones that 
failed  to  form  myotubes  after  transfection  with  MyoD1 
showed no MyoD1 expression (data not shown). We also iso- 
lated three MyoDl-transfected cell lines that were able to 
form myotubes at early passages, but that subsequently lost 
that  ability.  Northern  analysis  of  RNA  from  these  cells 
showed that MyoD1 was no longer expressed after the cells 
became fusion defective (data  not shown).  We  have con- 
tinued  to  follow the  properties of several  clonal  lines  of 
MyoDl-transfected BC3H1 cells  over a  period  of several 
months and have found that the expression of MyoD1 and the 
ability to fuse are progressively lost with time. It is unclear 
whether BC3H1 cells may have a mechanism for extinguish- 
ing MyoD1 expression. 
Myogenin and MyoD1 Positively Regulate Their Own 
Expression in 10T1/2 Cells 
The  observation  that  MyoD1  was  required  for  fusion  of 
BC3H1 cells prompted us to examine whether 10T1/2 cells 
that had acquired the ability to form myotubes after transfec- 
tion with myogenin (5) might express MyoD1. Two stably 
transfected lines of 10T1/2 cells, designated  10TFL2-3 and 
10TFL2-1, harboring a myogenin cDNA under control of the 
MSV-LTR were examined and were found to express myo- 
genin at high levels under both growth and differentiating 
conditions (Fig. 4 A). Myogenin was expressed in these cell 
lines at approximately the level it was expressed in differen- 
tiated BC3HI  myocytes (data not shown).  MyoD1  mRNA 
was  undetectable when the myogenin-transfected cell lines 
were maintained in mitogen-rich medium.  However, upon 
transfer to mitogen-deficient medium, MyoD1 mRNA was 
detected. These results show that MyoD1 is regulated, either 
directly or indirectly, through a myogenin-dependent path- 
way and that activation of MyoD1 expression by myogenin 
is dependent upon the removal of mitogens from the medium. 
Because myogenin is  able to regulate the expression of 
MyoD1, we investigated whether MyoD1 could activate the 
expression of myogenin. Two clonal cell lines,  designated 
M1 and M2, were isolated after stable transfection of 10TI/2 
ceils with MyoDl under control of the MSV-LTR. Clone M1 
showed low levels of myogenin in the presence of growth 
medium  and  high  levels  soon  after  transfer  to  mitogen- 
deficient medium (Fig. 4 B). In contrast, even when main- 
tained at low density in mitogen-rich medium, clone M2 ex- 
pressed MyoD1 at a fourfold higher level than clone M1 and 
had  a  tendency  to  differentiate  precociously.  The  early 
differentiation of the M2 cell line is demonstrated by the ex- 
pression of muscle creatine kinase in growth medium (Fig. 
4 B). The behavior of this cell line was consistent with that 
observed by Davis et al. (3), who reported that high-level ex- 
pression of MyoD1  causes cells to exit the cell cycle and 
differentiate in spite of high mitogen concentrations. Myo- 
genin was expressed at high levels by M2 cells under both 
growth and differentiating conditions. The high level of ex- 
pression in growth medium seems to reflect the fact that this 
cell line differentiates precociously. The behavior of stably 
transfected cell lines that we have analyzed thus far suggests 
that MyoD1 is more effective than myogenin in retarding the 
rate of cell growth in mitogen-rich medium, as several Myo- 
Figure  4.  MyoD1 and  myogenin regulate each 
others'  expression  in  transfected  101"1/2 cells. 
Clonal cell lines derived from 101"1/2  cells, desig- 
nated 10TFL2-3 and  10TFL2-1 (A), and MI and 
M2 (B), were isolated after transfection with myo- 
genin or MyoD1, respectively, under control of  the 
MSV-LTR. Cells were maintained at subconfluent 
density in growth medium (G) or at confluent den- 
sity in differentiation medium (D) for 4 d. Total 
cellular RNA was isolated from each cell line un- 
der the indicated conditions and was analyzed for 
expression of myogenin, muscle creatine kinase 
(MCK), and MyoDl mRNAs. A shows ethidium 
bromide staining to confirm that equivalent quan- 
tities of RNA were electrophoresed on each lane. 
Ethidium  bromide  staining also  confirmed that 
equivalent quantities  of RNA  were  electropho- 
resed on each lane in B (data not shown). 
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have not observed this phenomenon with myogenin transfec- 
tants. Together, these results show that forced expression of 
MyoD1 or myogenin in 101"1/2  cells leads to activation of the 
other member of the pair. Similar results were reported re- 
cently by Thayer et al.  (38). 
u-Cardiac Actin and MLC-lf Are Expressed by 
MyoDl-transfected BC  jH1 Ceils 
a-Cardiac  actin  is  the  predominant  a-actin  isoform  ex- 
pressed during differentiation of C2 cells and primary myo- 
blasts (1, 24). Strauch and Reeser (33) reported that a-cardiac 
actin mRNA was below the levels of detection in differen- 
tiated  BC3H1 myocytes. BC3HI  cells  also  do not  express 
skeletal muscle alkali  MLC-If during differentiation (36). 
MLC-lf and  -3f  are  derived  from a  single  gene  and  are 
generated by alternative splicing of a primary transcript that 
is  transcribed from two promoters (26,  34).  The MLC-lf 
and -3f promoters can be regulated independently (34), de- 
spite the fact that the MLC-1/3 locus is under the control of 
a muscle-specific enhancer that acts in a promoter-indepen- 
dent manner (4). BC3H1 cells provide an example of inde- 
pendent regulation of these promoters, because these cells 
selectively express MLC-3f at high levels during differenti- 
ation (36). Since the expression of MyoD1 was sufficient to 
rescue the ability of BCaH1 cells to fuse,  we investigated 
whether a-cardiac actin and MLC-lf expression were also 
restored in MyoDl-transfectants. 
In agreement with findings from previous studies (33, 36), 
there was  no detectable expression of a-cardiac  actin  or 
MLC-lf mRNA  in  BC3H1 cells  (Fig.  5).  However, these 
transcripts were induced in the BMD-1 cell line after transfer 
to differentiation medium. From densitometric analysis, the 
levels of expression of a-cardiac actin and MLC-lf mRNAs 
were •10-fold  lower in BMD-1  myotubes than in C2 myo- 
tubes,  however, it is  clear that they were significantly in- 
duced above the level in the parental BC3H1 cell line. The 
lower level of expression of a-cardiac actin and MLC-I~ in 
BMD-1 myotubes than in C2 cells cannot be attributed to an 
overall reduction in the extent of  differentiation  of  these cells, 
because Troponin-T was expressed at similar levels in all of 
the cell lines under differentiating conditions. That the exog- 
enous MyoD1 gene is expressed at a lower level in BMD1 
cells compared to C2 cells may explain the corresponding 
reduction in MLC-lf and a-cardiac actin expression in these 
cells. Expression of a-cardiac actin mRNA was also observed 
in five additional MyoDl-transfected clones of BCjH1  cells 
and in two independent pools of clones. MyoDl-transfected 
BC3H1 cells that no longer expressed MyoD1 and had lost 
the potential to fuse also lost the ability to express a-cardiac 
actin and MLC-lf (data not shown).  We conclude that the 
genes encoding a-cardiac actin and MLC-lf are potentially 
functional in BC3H1 cells and that their expression can be 
activated by MyoD1. 
We were able to detect faint signals in the region of the 
MLC-lf and a-cardiac actin transcripts after prolonged ex- 
posure to film of Northern blots of BC3H1 RNA.  If these 
signals  indeed  represented  MLC-L  and  a-cardiac  actin 
mRNAs,  their levels of expression were at least  100-fold 
lower than the levels in C2 myotubes (10-fold lower than the 
levels in BMD-1 cells). It should be mentioned that Taubman 
Figure 5.  Expression of u-cardiac  actin and MLC-If in MyoD1- 
transfected BC3H1 cells. Total cellular RNAs were isolated from 
BC3H1,  BMD-I,  and  C2  cells  maintained  in  growth (G)  or 
differentiation (D) medium, as indicated. RNA blots were hybrid- 
ized to 32p-labeled probes for a-cardiac actin, TnT,  and MLC-I, as 
indicated. Ethidium bromide  staining confirmed that equivalent 
quantities of RNA were electrophoresed on each lane (data not 
shown). Densitometry  showed that a-cardiac  actin and  MLC-I 
were expressed at a 10-fold higher level in C2 myotubes than in 
BMD-1 myotubes. 
et al. (36) reported the expression of a-cardiac actin mRNA 
in  BC3H1 cells.  This  disparity  could  be  explained  by 
differential modulation of the actin gene in different sub- 
clones of BC3H1 cells or under subtly different culture con- 
ditions. 
The Ability to Fuse Is Not EJ~iciently Rescued in 
BC  d-I1 Cells by 5-Azacytidine 
101"1/2 cells are efficiently converted to myoblasts that ex- 
press MyoD1 and form multinucleate myotubes after brief 
treatment with 5-azacytidine (13, 14,  37). We therefore in- 
vestigated whether treatment with 5-azacytidine could acti- 
vate  the  MyoD1  gene  and  rescue  the  ability  to  fuse  in 
BC3H1 cells.  To address  this  question,  BC3H1 cells were 
exposed to  10 #M 5-azacytidine for 24 h; cells were then 
plated at clonal density and allowed to form colonies.  14 d 
later, cultures were transferred to differentiation medium and 
their morphology was examined over the ensuing 10 d. In the 
more than 500 individual BC3H1 colonies we examined, no 
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dine-treated BC3H1 cells were isolated and analyzed for ex- 
pression of MyoD1, but none was detected (data not shown). 
Consistent with previous studies (13, 14, 37), 23%  (23 out 
of 100 colonies) of 10"1"1/2 colonies treated with 5-azacyti- 
dine generated extensive myotubes. Since BC3H1 cells are 
already myogenic, we anticipated that they would be con- 
verted to a fusion-competent, MyoDl-positive phenotype by 
5-azacytidine with an efficiency at least equivalent to that of 
10T1/2 cells. However, our results show that if 5-azacytidine 
can convert BC3H1 cells to a fusion-competent phenotype, 
the frequency for conversion must be at least two orders of 
magnitude lower than that for 10"I"1/2 cells. 
Discussion 
The results of this study show that the failure of BC3H1 
cells to activate the complete repertoire of events associated 
with myogenesis is caused by the lack of MyoD1 expression. 
Because an exogenous MyoD1 gene can rescue some aspects 
of the differentiation program that are defective in BC3H1 
cells, the genes required for normal differentiation  are poten- 
tially functional in BC3I-I1 cells  and can be  activated by 
MyoD1. The fact that myogenin is expressed at high levels 
in BC3H1 cells but is unable to activate the complete differ- 
entiation program also suggests that the functions of myoge- 
nin and MyoD1, while overlapping, are distinct. 
Although BC3H1 cells possess  a  MyoD1  gene that ap- 
pears at a gross level to be structurally normal, the gene is 
refractory to activation by MyoD1  or myogenin or by ex- 
posure to the demethylating agent 5-azacytidine, all of which 
are sufficient to activate MyoD1 expression in 101"1/2 cells. 
There are several  possible explanations for the inability of 
myogenin or MyoD1 to activate expression of the MyoD1 
gene in BC3H1 cells. The MyoD1 gene may possess a struc- 
tural alteration that is undetectable by Southern analysis but 
that prevents its activation. Alternatively, BC3H1 cells may 
lack one or more cellular factors that cooperate with myoge- 
nin and MyoD1 to activate the MyoD1 gene. Finally, BC3H1 
cells may express a negative regulatory factor that prevents 
activation of the MyoD1 gene by myogenin or MyoD1. Het- 
erokaryon experiments should distinguish among these pos- 
sibilities. 
Developmental  studies  have  shown  that  myogenin and 
MyoD1 have distinct patterns of expression during develop- 
ment and are not always coexpressed (29, see also 3, 5, 41). 
BC3H1  cells  may  represent  a  cell  line  derived  from  a 
specific stage of development in which MyoD1  is not nor- 
mally expressed. Repression of MyoD1 expression in certain 
developmental stages could be due to positive or negative 
regulatory factors, or could be a consequence of chromo- 
somal  structure.  If the  inactivation of MyoD1  in  BC3H1 
cells is not the consequence of a  gene defect, these cells 
would present a  particularly attractive system in which to 
study different myogenic developmental stages. 
The frequency of conversion of 10T1/2 cells to myoblasts 
by 5-azacytidine is consistent with the involvement of one or 
a few closely linked loci (13, 14, 37).  The low efficiency of 
conversion of BC3H1 cells to a fusion-competent phenotype 
suggests either that multiple genes must be demethylated to 
rescue the ability to fuse, or that a single gene that is required 
for fusion cannot be activated by 5-azacytidine in these cells. 
Our  results  show that myogenin and MyoD1  positively 
regulate each  other's  expression  in  10"I"1/2 cells  and that 
mitogens interfere with this transactivation. Thayer et al. 
(38) also reported recently that MyoD1 and myogenin acti- 
vate expression of the endogenous MyoD1 allele in certain 
types of cells. Based on these observations, they proposed 
that this type of regulatory loop may provide a mechanism 
whereby these regulatory factors can amplify their own ex- 
pression above a critical threshold required for activation of 
and commitment to myogenic differentiation. The fact that 
BC3H1 cells are unable to terminally differentiate is consis- 
tent with their failure to regulate MyoD1. Considering the 
extensive homology between myogenin and MyoD1  within 
the myc similarity domain (3, 5, 35, 41), it is likely that the 
cross activation between these factors is mediated by their 
homologous domains. 
That mitogens prevent myogenin-dependent activation of 
MyoD1 and other muscle-specific genes, suggests that myo- 
genin acts on these genes through a common mechanism. In 
this regard, it has been shown that MyoD1 (15) and myogenin 
(T. J. Brennan and E. N. Olson, Genes & Dev., in press) in- 
teract with the muscle creatine kinase enhancer core. In ad- 
dition, myogenin binds to its own promoter (T. Chakraborty 
and E. Olson, our unpublished observations). The mecha- 
nism through which mitogenic signals block the actions of 
myogenin and MyoD1 also remain to be established. We have 
shown previously that growth factor-dependent repression 
of muscle-specific genes requires protein synthesis, suggest- 
ing that growth factor-inducible early gene products may act 
as negative regulators of myogenesis (32).  Thus, growth fac- 
tor-inducible nuclear factors might interfere either directly 
or indirectly with interactions between myogenin and MyoD1 
and their appropriate cellular targets. Consistent with this 
hypothesis is the observation that fos (16, 40) and JunB (L. 
Li, T. Brennan, and E. Olson, unpublished results) prevent 
activation of the muscle creatine kinase enhancer by myogenin. 
Thus far,  the biologic actions of myogenin and MyoD1 
have been found to be indistinguishable. However, since fu- 
sion and expression of the c~-cardiac actin and MLC-lf genes 
can be activated by MyoD1  in BC3H1 cells, it appears that 
subtle differences exist between the activities of myogenin 
and MyoD1 as activators of muscle genes. The most straight- 
forward interpretation of  these observations is that the a-car- 
diac actin and MLC-lf genes, in addition to one or more 
genes that are required for fusion and terminal differentia- 
tion, are directly dependent on MyoD1 or on factors that are 
regulated specifically by MyoD1.  This model predicts that 
myogenin does not act alone to control all aspects of the 
differentiation program but instead cooperates with MyoD1 
and perhaps other regulatory factors to regulate myogenesis. 
The susceptibility of various nonmyogenic cell lines to myo- 
genic conversion by myogenin or MyoD1  (40)  may, there- 
fore, be dictated by whether either of the endogenous genes 
can be activated. 
The expression of only certain aspects of the myogenic 
program is not unique to BC~H1 cells. Rat L6 myobtasts, 
for example, also exhibit a defect in differentiation and do not 
express a-cardiac actin, MLCs 1 and 3 and one of two myo- 
sin heavy chain components when they fuse to form myo- 
tubes  (9).  The  phenotype  of  BC.~I-I1 cells  also  closely 
resembles that of the L6E9-3b2 cell line, which was derived 
from L6 (20).  These cells are temperature sensitive for fu- 
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missive temperatures they reversibly induce sarcomeric con- 
tractile  protein  genes,  but do  not  fuse.  Interestingly,  L6 
myoblasts also do not express  MyoD1  at detectable  levels 
(41).  It  remains  to  be  determined  whether an  exogenous 
MyoDl gene can restore all aspects of the differentiation pro- 
gram in this system.  The fact that L6 myoblasts form myo- 
tubes but do not express MyoD1 may indicate that fusion can 
be triggered through a MyoDl-independent mechanism. Per- 
haps other regulatory factors,  e.g.,  myf-5  (2),  may be ex- 
pressed  in L6  myoblasts  and compensate  partially for the 
lack of MyoD1. 
Elucidation of the mechanism that prevents activation of 
MyoDl  in BC3H1 cells should shed light on the regulatory 
events that control MyoD1 expression during development. 
BC3HI  cells  should also  provide  an  important system  for 
identifying genes that depend specifically on MyoD1 for ex- 
pression and should facilitate the analysis of the specific ac- 
tions of myogenin in the absence of MyoD1. 
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